Pathology

Sociology

Grading (engineering)

Disease

Coronavirus disease 2019 (COVID-19)

Narrative review

Social science

Economic growth

Family medicine

Infectious disease (medical specialty)

Civil engineering

Engineering

Political science

Intensive care medicine

Cognitive psychology

Psychology

Health care

Economics

Multidisciplinary approach

Alternative medicine

Checklist

MEDLINE

Guideline

Medicine

Clinical Infectious Diseases

Background There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. The objective was to develop evidence-based rapid guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. Methods The Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and gray literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Results The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. Conclusions The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)